A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)
Categories (click each to see list of all clinical trials associated with that category): Gastrointestinal (GI)
Current Status: Open to accrual
Phase: III
Principal Investigator: Klute, Kelsey
Contact Information:
Brandie Booker, RN
402-559-8197
brandie.booker@unmc.edu
Eligibility: https://www.clinicaltrials.gov/ct2/show/NCT03847428?cond=NCT03847428&draw=2&rank=1#eligibility
Summary